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Summary In a phase I study of weekly administered cisplatin combined with oral etoposide, we observed a
partial response in 4 out of 11 patients with metastatic colorectal cancer. Subsequently, we performed a phase
II study to investigate the activity of this combination as first-line treatment in this disease. Fourteen patients
with metastatic colorectal cancer were enrolled in this study. Treatment consisted of cisplatin, administered in
3% sodium chloride, at a dose of 70 mg m-2 on days 1, 8 and 15 and days 29, 36 and 43 combined with oral
etoposide 50 mg absolute dose daily on days 1-15 of both courses. Patients with stable disease or better
continued treatment with etoposide 50 mg m 2 orally on days 1-21 every 28 days. A partial response was
observed in two patients with liver metastases (14%; 95% confidence limits 2-42%) for 30 and 32 weeks. Five
patients had stable disease. Toxicity consisted mainly of anaemia, leucocytopenia, nausea and vomiting.
Tinnitus was reported by six patients. The activity of the combination cisplatin-oral etoposide in this schedule
is only minimal in metastatic colorectal cancer.
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The poor prognosis for numerous patients with metastatic
colorectal cancer is an incentive for oncologists to explore
new treatments for this disease. The combination of
fluorouracil with leucovorin is nowadays the more or less
accepted standard treatment, but the optimum treatment
schedule still has to be defined (Moertel, 1994). Cisplatin as a
single agent at standard doses is inactive in colorectal cancer
(DeSimone et al., 1986) but in combination with fluorouracil
a modest activity has been reported (Posner et al., 1987;
LoRuss et al., 1989; Kemeny et al., 1990). Etoposide as a
single agent given intravenously is inactive in colorectal
cancer (Perry et al., 1976; Douglass et al., 1979). As
colorectal tumours are in general slow growing, a more
prolonged administration of cytotoxic drugs may be
advantageous. Oral etoposide can be given over a long
period of time with acceptable toxicity (Greco et al., 1990).
Activity of oral etoposide has been shown in small-cell and
non-small-cell lung cancer, germ cell tumours and breast
cancer. In a phase I study of weekly cisplatin combined with
oral etoposide a partial response was observed in 4 out of 11
patients with metastatic colorectal cancer, most of them
pretreated with fluorouracil (Planting et al., 1995). We
performed a phase II study with this combination in
chemonaive patients with metastatic colorectal cancer. A
response rate of >40% was considered of interest because
lower response rates can be obtained easily with milder
regimens.
Patients and methods
Patients were required to have histologically proven colo-
rectal cancer with measurable metastases, a WHO perfor-
mance status of 2 or better, white blood cell count > 3.0 x
109 -1, platelet count >100 x 109 1-, creatinine clearance
>60 ml min- and serum bilirubin <25 jumol 1 '. All
patients had full medical history and physical examination
before start of treatment, a chest radiograph, CT scan of the
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abdomen with intravenous contrast and, on indication, CT
scan of the chest and an ECG. All patients had a
neurological examination including vibration perception
threshold (VPT).
During treatment patients had weekly physical examina-
tions and assessment of toxicity, weekly full blood counts and
estimation of electrolytes, calcium and magnesium and
creatinine clearance. Neurological examination including
VPT was repeated after the cisplatin treatment period.
Response to treatment was assessed 2 weeks after the last
cisplatin administration. The standard WHO criteria were
used for evaluation of response and toxicity (WHO, 1979).
Treatment Schedule
Cisplatin was administered at a dose of 70 mg m-2 on days
1, 8 and 15 and days 29, 36 and 43; oral etoposide was
administered at a dose of 50 mg daily on days 1- 15 and days
29-43. During cisplatin administration patients were
hospitalised for 24 h. The treatment regimen consisted of
prehydration with 1000 ml dextrose saline + 20 mmol
potassium chloride + 1 g magnesium sulphate over 4 h;
cisplatin powder was dissolved in 250 ml 3% sodium chloride
and administered over 3 h followed by post-hydration with
2 1 of dextrose saline + 40 mmol potassium chloride + 2 g
magnesium sulphate over 8 h. The anti-emetic regimen
consisted of 8 mg ondansetron slow i.v. bolus directly
before the start of the cisplatin infusion and was repeated if
necessary.
In this study dose reductions were not allowed. If at the
day of planned cisplatin administration WBC was <2.5 x
109 1-1 and/or platelets were <75 x 109 -1 treatment was
postponed until recovery above these values with a maximum
delay of 2 weeks. In case of a delay > 2 weeks or in case of
nephro- or neurotoxicity > WHO grade 2 patients were to be
taken off the study.
Patients responding to treatment or patients with stable
disease at response evaluation continued treatment with oral
etoposide at a dose of 50 mg m-2 day-' on days 1-21 every
28 days for a maximum of four cycles. Etoposide was
administered as 50 mg gelatin capsules and the dosage was
adjusted such that the total etoposide dose administered
during the planned treatment period deviated < 5% from the
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patients had full blood counts every 2 weeks and estimation
of electrolytes, liver and renal functions every 4 weeks.
Tumour response evaluation was repeated every 8 weeks.
Results
Fourteen patients were entered into the study. The patient
characteristics are given in Table I. All patients were
chemonaive with the exception of one patient who had
adjuvant chemotherapy after surgery more than 1 year before
entry in this study. In general, the treatment was tolerated
well. In total the 14 patients received 80 administrations of
cisplatin; median six per patient (range 3-6). A delay in
cisplatin administration was necessary in only six cycles (1 x
cycle 3, 4 x cycle 4, 1 x cycle 5) for a total of 12 weeks delay.
Seven patients continued with oral etoposide after
response evaluation. One patient received only one course,
one patient two courses, one patient three courses and the
other four patients completed the maximum of four courses.
In three out of the 22 courses given, a 1 week delay was
necessary because of delayed bone marrow recovery.
Responses
Thirteen patients were evaluable for response. One patient,
with a pelvic local recurrence only, was considered not
evaluable because of an inevaluable parameter on CT scan
but is included in the toxicity analysis. A partial response was
observed in two patients with liver metastases with a duration
of 30 and 32 weeks yielding a response rate of 14% (95% CI
2-44%). Five patients had stable disease with a median time
until progressive disease of 22 weeks (range 12-56 weeks).
Six patients progressed during treatment. In none of the
patients did the response status improve during the oral
etoposide treatment.
Toxicity
The side-effects observed were mainly bone marrow
suppression and nausea and vomiting. The side-effects are
shown in Table II. The table shows the worst side-effects
observed during treatment overall, including the side-effects
during the 'maintenance' treatment with oral etoposide.
Anaemia occurred frequently and six patients needed
transfusions for a total of 26 units of packed cells.
Leucocytopenia grade 4 was observed in only one patient.
The median nadir of leucocytes was 3.0 x 109 1-' (range 0.6-
6.0). Thrombocytopenia grade 3 occurred in only two
patients. Median nadir of platelets was 99 x 109 I` (range
47-324). Neurotoxicity grade 1 was observed in four
patients. Results of VPT measurements were included in a
separate report (Hilkens et al., 1994). Six patients reported
tinnitus as a side-effect. There were no patients with
nephrotoxicity.
Discussion
The combination of fluorouracil with leucovorin is at this
moment accepted as 'standard' treatment in metastatic
colorectal cancer with an overall response rate of 23%.
Various schedules have been explored with similar response
rates. The combination of 5 day low-dose leucovorin with
moderate dose fluorouracil every 4-5 weeks is considered the
least toxic and most 'cost-effective' (Moertel, 1994).
In this phase II study we explored the value of frequently
administered high-dose cisplatin combined with oral etopo-
Table I Patient characteristics
Total no. of patients
Male-female ratio
Median WHO performance status (range)
Median age in years (range)
Location of primary tumour
Rectum
Sigmoid
Colon
Location of metastases
Liver only
Liver and lung
Liver and lymph node
Local pelvic recurrence
Prior therapies
Surgery
Adjuvant radiotherapy
Adjuvant 5-FU
Total administrations of CDDP
Total delays in weeks of CDDP
Total no. of patients with VP maintenance
Total no. of VP courses delayed
14
9:5
1 (0-1)
53 (40-63)
7
3
4
7
4
1
2
14
1
1
80
12
7
3
Table II Toxicity observed during CDDP-VP
WHO grading
(Worst toxicity per patient)
0 1 2 3 4
Anaemia 2 5 5 2 0
WBC 2 5 4 2 1
Platelets 6 4 2 2 0
Nausea/vomiting 0 1 8 5 0
Neurotoxicity 10 4 0 0 0
Nephrotoxicity 14 0 0 0 0
Ototoxicitya 8 0 6 0 0
Mucositis 13 0 1 0 0
aOtotoxicity: CTC grading.
side based on our observation that 4 out of 11 patients with
colorectal cancer responded in the phase I study. Unfortu-
nately, we were not able to confirm a valuable level of
activity of this regimen, nor was there a suggestion that
continuing treatment with oral etoposide was of any benefit
for these patients. A recent report (Zaniboni et al., 1995)
using oral etoposide as second-line treatment in colorectal
cancer was also completely negative. A phase II study using a
more conventional administration of cisplatin every 3 weeks
combined with etoposide i.v. on days 1, 3 and 5 at a dose of
100 mg m-2 and 100 mg m-2 showed a major response in
only 5 out of 33 patients (Passalacqua et al., 1991). In view of
these and our results there seems no role for etoposide in
colorectal cancer. Whether cisplatin is of any value in
colorectal cancer can also be debated. Although phase II
studies were moderately optimistic, prospective randomised
trials of 5-FU plus cisplatin (with or without leucovorin) vs
the same schedule without cisplatin did not show survival
benefit of the cisplatin arms (Loehrer et al., 1988; Labianca et
al., 1988; Scheithauer et al., 1994). A prospective randomised
trial comparing continuous fluorouracil infusion with a
combination with weekly low-dose cisplatin (20 mg m-2)
did not show any benefit of the combination (Lokich et al.,
1991). We therefore conclude that the combination of 5-FU
plus leucovorin is still the 'poor winner' and further studies
with new drugs remain essential.Phase II study of cisplatin/etoposide in colorectal cancer
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